Literature DB >> 1702352

Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?

M Välimäki1, H Järvinen, P Salmela, T Sane, S M Sjöblom, R Pelkonen.   

Abstract

Eight patients with metastatic carcinoid tumor, seven of whom had symptoms of the carcinoid syndrome, were treated with either human leukocyte interferon (seven patients) or recombinant alpha-interferon (IFN alpha-2b) (one patient) at doses of 4.5 to 21 x 10(6) IU weekly for 1 to 21 (mean, 8.5) months. Tumor regression on computed tomography (CT) scan was found in one patient, the CT findings remained unchanged in three, and the tumor progressed in four patients. A clearcut and continuing decrease in urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) was observed in one patient and a transient one in four patients. The symptoms improved in only two of seven patients. Four patients had leukopenia develop, which was circumvented by reducing the dose. The authors conclude that interferon therapy of the carcinoid tumor is not as successful as has been suggested in previous reports.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702352     DOI: 10.1002/1097-0142(19910201)67:3<547::aid-cncr2820670302>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  New developments in the treatment of gastrointestinal neuroendocrine tumors.

Authors:  Matthew H Kulke
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

Review 2.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

Review 3.  Systemic therapy for advanced pancreatic neuroendocrine tumors.

Authors:  Matthew H Kulke
Journal:  Semin Oncol       Date:  2013-02       Impact factor: 4.929

4.  Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Authors:  Keith Stuart; Donna E Levy; Tom Anderson; Constantine A Axiotis; Janice P Dutcher; Andrew Eisenberg; John K Erban; Al Bowen Benson III
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

Review 5.  Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

Authors:  Diane L Reidy; Laura H Tang; Leonard B Saltz
Journal:  Nat Clin Pract Oncol       Date:  2009-02-03

Review 6.  Interferons in the management of neuroendocrine tumors and their possible mechanism of action.

Authors:  K Oberg
Journal:  Yale J Biol Med       Date:  1992 Sep-Oct

Review 7.  Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.

Authors:  Cristina Saavedra; Jorge Barriuso; Mairéad G McNamara; Juan W Valle; Angela Lamarca
Journal:  Cancer Manag Res       Date:  2019-08-08       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.